Autopsy report · NCT00733798

A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma

“For Strategic Reasons”

The sponsor’s own words in the registry.

Life of this trial

• 58 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

TransMolecular

Sponsor type

Industry

Conditions

Melanoma; Malignant Melanoma; Metastatic Melanoma

Interventions

131I-TM601

Participants

58 (planned, not actual)

Sites

3

Countries

United States

Trials that died the same way

• Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
  “Strategic reasons” (90% match in meaning)
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (84% match in meaning)
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
  “for business reasons” (82% match in meaning)
• S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
  “Strategic development reasons” (77% match in meaning)
• IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE
  “for strategic and pandemic reasons” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.